ArticleFrontiers in public health2026
Global, regional, and national burden of alopecia areata in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Alopecia areata (AA) is a common autoimmune hair loss disorder, posing a significant threat to the mental health and quality of life of patients, especially adolescents and young adults at critical stages of psychological and social development. This study conducted a comprehensive comparative analysis of the burden of AA in the global population aged 10-24 years, providing scientific basis for the prevention and treatment of AA. Methods: Using data from GBD 2021, AA prevalence, incidence, and disability-adjusted life years (DALYs) for individuals aged 10-24 years in 204 countries and territories from 1990 to 2021 were analyzed by age, sex, and region. Temporal trends were evaluated by average annual percentage of change (AAPC) calculated by the Joinpoint regression model. Results: From 1990 to 2021, the number of prevalence cases, incidence cases, and DALYs of AA among individuals aged 10-24 worldwide increased, however, the corresponding age-standardized rates all decreased, with AAPCs of -0.1374 (95% CI: -0.1396 to -0.1354), -0.1404 (95% CI: -0.1425 to -0.1387), and -0.1351 (95% CI: -0.1382 to -0.1317), respectively. The burden of AA in females was higher than that in males, and both decreased, with a more significant decrease in males; the 20-24 group had the largest rate decline but remained most burdened; the burden in high socioeconomic indices (SDI) regions was the highest, but the decrease was the most significant; the burden in North America was the highest, while the burden in South Asia, Western Europe, and North Africa and the Middle East regions showed an upward trend; the burden in the United States was the highest, but the decline was the greatest, and the increase was the largest in the United Arab Emirates. Conclusion: The absolute burden of AA among adolescents and young adults worldwide was still increasing, but the age-standardized rates had slightly decreased. There were significant age, gender, regional, and socioeconomic inequalities in the burden distribution. These differences should be fully considered, and comprehensive prevention, treatment, and psychological support measures should be adopted to continuously monitor and formulate precise strategies for AA in adolescents and young adults, reducing its burden and profound psychological impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.